Liberty Broadband (LBRDK) Projected to Post Quarterly Earnings on Friday

Liberty Broadband (NASDAQ:LBRDK) is anticipated to issue its quarterly earnings data before the market opens on Friday, February 21st. Analysts expect the company to announce earnings of $2.72 per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Liberty Broadband Trading Up 2.0 %

Shares of LBRDK opened at $81.06 on Friday. The company has a market capitalization of $11.58 billion, a P/E ratio of 14.93 and a beta of 1.04. Liberty Broadband has a one year low of $46.46 and a one year high of $101.50. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.07 and a current ratio of 2.07. The stock has a 50-day moving average price of $77.92 and a 200 day moving average price of $75.79.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Liberty Broadband in a research note on Sunday, February 9th. They set a “sell” rating on the stock.

Insider Buying and Selling at Liberty Broadband

In other Liberty Broadband news, CEO Gregory B. Maffei sold 71,500 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $82.00, for a total transaction of $5,863,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,827,013 shares of the company’s stock, valued at approximately $231,815,066. This trade represents a 2.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 196,542 shares of company stock valued at $15,834,108. 10.80% of the stock is owned by corporate insiders.

Liberty Broadband Company Profile

Liberty Broadband Corporation engages in the communications businesses. The company's GCI Holdings segment provides data, wireless, video, voice, and managed services to residential customers, businesses, governmental entities, educational, and medical institutions in Alaska under the GCI brand.